EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application solifenacin succinate tablets, 5mg, and 10mg. Aurobindo Pharma’s solifenacin succinate tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), VESIcare Tablets, manufactured by Astellas Pharma US, Inc.
Solifenacin succinate tablets, are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin succinate tablets, has an estimated market size of US $28 Million for the twelve months ending October 2022, as per IQVIA.
Comments are closed.